Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Akebia TherapeuticsWave Life SciencesAvadel Pharmaceuticals89bioMarinus Pharmaceuticals
SymbolNASDAQ:AKBANASDAQ:WVENASDAQ:AVDLNASDAQ:ETNBNASDAQ:MRNS
Price Information
Current Price$2.97$6.11$8.49$28.00$14.16
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.81.81.51.61.7
Analysis Score3.33.33.53.63.5
Community Score2.72.62.42.92.8
Dividend Score0.00.00.00.00.0
Ownership Score1.72.50.81.71.7
Earnings & Valuation Score1.30.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$9.63$11.80$18.60$61.88$28.75
% Upside from Price Target224.07% upside93.13% upside119.08% upside120.98% upside103.04% upside
Trade Information
Market Cap$434.41 million$299.37 million$478.24 million$517.10 million$518.72 million
Beta2.110.351.55N/A1.72
Average Volume6,110,728820,890470,263151,231324,003
Sales & Book Value
Annual Revenue$335 million$15.98 million$59.22 millionN/AN/A
Price / Sales1.3618.738.38N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.32 per share$1.86 per share($0.78) per share$6.92 per share$2.90 per share
Price / Book0.893.28-10.88N/AN/A
Profitability
Net Income$-279,660,000.00$-193,640,000.00$-33,230,000.00$-57,420,000.00$-54,120,000.00
EPS($1.63)($5.72)($0.89)($24.49)($3.96)
Trailing P/E RatioN/AN/A42.45N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-126.86%-1,562.01%38.70%N/AN/A
Return on Equity (ROE)-68.51%-401.32%-33.91%-49.56%-95.56%
Return on Assets (ROA)-34.01%-72.82%-11.75%-46.52%-66.01%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.24%N/A0.74%N/AN/A
Current Ratio2.15%1.33%12.24%23.61%10.08%
Quick Ratio1.67%1.33%12.24%23.61%10.08%
Ownership Information
Institutional Ownership Percentage68.98%80.67%53.78%80.63%79.32%
Insider Ownership Percentage2.55%38.20%1.41%18.10%2.80%
Miscellaneous
Employees379301322565
Shares Outstanding153.50 million49.00 million58.47 million20.04 million36.63 million
Next Earnings Date5/4/2021 (Estimated)5/10/2021 (Estimated)5/10/2021 (Estimated)5/12/2021 (Estimated)5/3/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Marinus Pharmaceuticals Inc (MRNS)Marinus Pharmaceuticals Inc (MRNS)
investing.com - April 18 at 10:55 PM
If You Had Bought Marinus Pharmaceuticals (NASDAQ:MRNS) Stock A Year Ago, You Could Pocket A 101% Gain TodayIf You Had Bought Marinus Pharmaceuticals (NASDAQ:MRNS) Stock A Year Ago, You Could Pocket A 101% Gain Today
finance.yahoo.com - April 16 at 1:21 PM
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - April 12 at 6:21 PM
Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Gap Down to $15.52Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Gap Down to $15.52
americanbankingnews.com - April 12 at 11:30 AM
Marinus Pharmaceuticals Bolsters Leadership Team with Two New AppointmentsMarinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments
finance.yahoo.com - April 12 at 8:21 AM
Marinus Pharmaceuticals (NASDAQ:MRNS) Trading Up 3.1%Marinus Pharmaceuticals (NASDAQ:MRNS) Trading Up 3.1%
americanbankingnews.com - April 9 at 12:32 PM
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Rating of "Buy" by BrokeragesMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - April 4 at 6:22 AM
Marinus (MRNS) Gets a Buy Rating from Leerink PartnersMarinus (MRNS) Gets a Buy Rating from Leerink Partners
smarteranalyst.com - March 11 at 12:25 PM
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue EstimatesMarinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 9 at 2:28 PM
Marinus Pharmaceuticals: Q4 Earnings SnapshotMarinus Pharmaceuticals: Q4 Earnings Snapshot
apnews.com - March 9 at 9:27 AM
Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for CommercializationMarinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization
finance.yahoo.com - February 23 at 8:06 AM
Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences ConferencesMarinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences
markets.businessinsider.com - February 17 at 7:03 AM
What Kind Of Shareholders Own Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?What Kind Of Shareholders Own Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?
finance.yahoo.com - February 15 at 9:34 AM
Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status EpilepticusMarinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus
finance.yahoo.com - January 26 at 9:49 AM
MRNS Feb 2021 14.000 callMRNS Feb 2021 14.000 call
in.finance.yahoo.com - January 23 at 6:32 PM
MRNS Feb 2021 16.000 callMRNS Feb 2021 16.000 call
in.finance.yahoo.com - January 20 at 5:23 PM
MRNS Feb 2021 11.000 putMRNS Feb 2021 11.000 put
in.finance.yahoo.com - January 20 at 5:23 PM
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in ...Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in ...
businesswire.com - January 13 at 11:05 PM
Stock Alert: Marinus Pharmaceuticals Climbs 11%Stock Alert: Marinus Pharmaceuticals Climbs 11%
nasdaq.com - January 13 at 1:04 PM
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)
finance.yahoo.com - January 13 at 8:01 AM
MRNS Jan 2021 8.000 putMRNS Jan 2021 8.000 put
ca.finance.yahoo.com - January 7 at 12:30 AM
Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect ConferenceMarinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference
finance.yahoo.com - January 6 at 9:29 AM
5 Disruptive Biotech Stocks With Solid Long-Term Potential5 Disruptive Biotech Stocks With Solid Long-Term Potential
finance.yahoo.com - January 4 at 12:58 PM
MRNS Jan 2021 17.000 putMRNS Jan 2021 17.000 put
in.finance.yahoo.com - December 23 at 10:52 PM
MRNS Jan 2021 10.000 putMRNS Jan 2021 10.000 put
uk.finance.yahoo.com - December 23 at 12:58 AM
DateCompanyBrokerageAction
3/15/2021Akebia TherapeuticsHC WainwrightLower Price Target
3/15/2021Akebia TherapeuticsCantor FitzgeraldInitiated Coverage
1/29/2021Akebia TherapeuticsJPMorgan Chase & Co.Downgrade
9/4/2020Akebia TherapeuticsMorgan StanleyLower Price Target
9/4/2020Akebia TherapeuticsBTIG ResearchLower Price Target
9/4/2020Akebia TherapeuticsMizuhoLower Price Target
8/11/2020Akebia TherapeuticsNeedham & Company LLCInitiated Coverage
5/6/2020Akebia TherapeuticsRoyal Bank of CanadaBoost Price Target
3/30/2021Wave Life SciencesTruistLower Price Target
3/30/2021Wave Life SciencesSVB LeerinkLower Price Target
12/31/2019Wave Life SciencesSunTrust BanksReiterated Rating
12/17/2019Wave Life SciencesGuggenheimLower Price Target
12/16/2019Wave Life SciencesCowenReiterated Rating
11/9/2020Avadel PharmaceuticalsLifesci CapitalReiterated Rating
8/11/2020Avadel PharmaceuticalsCi CapitalReiterated Rating
7/30/2020Avadel PharmaceuticalsOppenheimerInitiated Coverage
5/4/2020Avadel PharmaceuticalsPiper SandlerBoost Price Target
4/3/2020Avadel PharmaceuticalsCraig HallumBoost Price Target
4/3/2020Avadel PharmaceuticalsJefferies Financial GroupInitiated Coverage
3/12/2020Avadel PharmaceuticalsStifel NicolausInitiated Coverage
9/24/2019Avadel PharmaceuticalsLaidlawBoost Price Target
6/14/2019Avadel PharmaceuticalsLADENBURG THALM/SH SHUpgrade
8/7/2018Avadel PharmaceuticalsJMP SecuritiesDowngrade
3/25/202189bioChardan CapitalBoost Price Target
10/19/202089bioRaymond JamesInitiated Coverage
9/25/202089bioBank of AmericaUpgrade
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.